The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

It comes amid reports that the drugs maker is considering moving its listing from the UK to the US in what would be a hammer ...

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

Bengaluru: A war of words has erupted between Biocon founder Kiran Mazumdar-Shaw and Karnataka Chief Minister Siddaramaiah on ...

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

Experts and agencies reject any link between COVID-19 vaccines and sudden cardiac deaths, citing studies showing no causal ...